My letter to Eli Lilly (makers of Solanezumab)

Dear Sirs
Today the media was full of reports about Solanezumab, your proposed drug to prevent or curtail the progression of Alzheimers Disease through interaction with amyloid plaques. I am curious to know what data you based this claim on as in January 2014 the New England Journal of Medicine reported that, in Phase 3 trials,”Solanezumab, a humanized monoclonal antibody that binds amyloid, failed to improve cognition or functional ability.”
I am confused that it is now being touted as a wonder drug. I would be grateful if you could provide an explanation.
 
Yours faithfully
Advertisements